Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity
- First Online:
- 425 Downloads
Cutaneous adverse reactions are reported for many treatments including antiosteoporotic agents. This position paper includes an algorithm for their recognition. With early recognition and proper management, including immediate and permanent withdrawal of the culprit agent, accompanied by hospitalization, rehydration, and systemic corticosteroids, if necessary, the prognosis is good.
Cutaneous adverse reactions are reported for many therapeutic agents and observed in between 0% and 8% of treated patients depending on the drug. The antiosteoporotic agents are reputed to be safe in terms of cutaneous effects; however, there have been a number of case reports of cutaneous adverse reactions, which merit consideration. This was the subject of a Working Group meeting of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis in April 2009, to focus on the impact of cutaneous adverse reactions and drug-induced hypersensitivity in the management of postmenopausal osteoporosis. We prepared this position paper following these discussions, and include an algorithm for their recognition.
We reviewed cutaneous adverse reactions observed with antiosteoporotic agents, including information from case reports, regulatory documents, and pharmacovigilance.
The cutaneous adverse reactions range from benign reactions including exanthematous or maculopapular eruption (drug rash), photosensitivity, and urticaria to the severe and potentially life-threatening reactions, angioedema, drug rash with eosinophilia and systemic symptoms (DRESS), Stevens Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). Review of available evidence shows that cutaneous adverse reactions occur with all commonly used antiosteoporotic agents. Notably, there are reports of SJS and TEN for bisphosphonates, and of DRESS and TEN for strontium ranelate. These severe reactions remain very rare (<1 in 10,000 cases).
With early recognition and proper management, including immediate and permanent withdrawal of the culprit agent, accompanied by hospitalization and rehydration and systemic corticosteroids if necessary, the prognosis is good.
KeywordsAnti-osteoporotic treatments Cutaneous adverse reactions Hypersensitivity reactions Osteoporosis
- 4.US Food and Drugs Administration (2009) PharmapendiumGoogle Scholar
- 6.Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 102:4134–39CrossRefPubMedGoogle Scholar
- 9.Mockenhaupt M (2007) Epidemiology and causes of severe cutaneous adverse reactions to drugs, pp 18–31Google Scholar
- 10.Eshki M, Allanore L, Musette P, Milpied B, Grange A, Guillaume JC, Chosidow O, Guillot I, Paradis V, Joly P, Crickx B, Ranger-Rogez S, Descamps V (2009) Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol 145:67–72CrossRefPubMedGoogle Scholar
- 18.Shiohara T, Takahashi R, Kano Y (2007) Drug-induced hypersensitivity syndrome and viral reactivation, pp. 251-266Google Scholar
- 20.Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128:35–44CrossRefPubMedGoogle Scholar
- 22.Allanore L, Roujeau JC (2007) Clinic and pathogenesis of severe bullous skin reactions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, pp. 267–277Google Scholar
- 26.European Medicines Agency (2008) Alendronate. Summary of product characteristicsGoogle Scholar
- 33.US Food and Drugs Administration (2002) Risedronate. DescriptionGoogle Scholar
- 34.(2009) Vidal 2009. Le Dictionnaire, 85th edGoogle Scholar
- 37.European Medicines Agency (2007) Ibandronate. Summary of product characteristicsGoogle Scholar
- 38.European Medicines Agency (2008) Zoledronic acid. Summary of product characteristicsGoogle Scholar
- 40.European Medicines Agency (2008) Strontium ranelate. Summary of product characteristicsGoogle Scholar
- 42.Boada A, Carrascosa J, Leal L, Ferrandiz C (2009) Generalized cutaneous drug eruption due to strontium ranelate. J Eur Acad Dermatol Venereol 0 (in press)Google Scholar
- 44.Jonville-Bera AP, Crickx B, Aaron L, Hartingh I, utret-Leca E (2009) Strontium ranelate-induced DRESS syndrome: first two case reports. Allergy Google Scholar
- 47.European Medicines Agency (2008) Raloxifene. Summary of product characteristicsGoogle Scholar
- 49.European Medicines Agency (2008) Teriparatide. Summary of product characteristicsGoogle Scholar
- 50.European Medicines Agency (2007) Parathyroid hormone. Summary of product characteristicsGoogle Scholar
- 52.McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–31CrossRefPubMedGoogle Scholar